Cargando…

Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics

Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID‐19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from the US Food and Drug Administ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ziteng, Chan, Eric Chun Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087009/ https://www.ncbi.nlm.nih.gov/pubmed/35380176 http://dx.doi.org/10.1002/cpt.2600

Ejemplares similares

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
por: Deprez, Valentine, et al.
Publicado: (2020)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
por: McInnes, Iain B., et al.
Publicado: (2019)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Pharmacokinetics of baricitinib in critically ill COVID-19 patients
por: Massart, Nicolas, et al.
Publicado: (2023)

Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy
por: George, Blessy, et al.
Publicado: (2020)

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
por: Amrhein, Jan, et al.
Publicado: (2020)

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review
por: Álvarez-Reguera, Carmen, et al.
Publicado: (2022)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection
por: Faquetti, Maria L., et al.
Publicado: (2022)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
por: Lee, Ji Sang, et al.
Publicado: (2019)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
por: Bergman, Martin, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Additional baricitinib loading dose improves clinical outcome in COVID-19
por: Hasan, Md Jahidul, et al.
Publicado: (2020)

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
por: Miyoshi, So, et al.
Publicado: (2019)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients
por: Pei, Ling, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19
por: Cho, Yong-Soon, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study
por: Zhao, Xia, et al.
Publicado: (2020)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

Kidney function and clinical recommendations of drug dose adjustment in geriatric patients
por: Karsch-Völk, Marlies, et al.
Publicado: (2013)

Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
por: Zhou, L, et al.
Publicado: (2015)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Tofacitinib
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7iknag2g8ma25svq83qbajf90b